



Enalare Therapeutics to Present at BIO-Europe Spring Conference

PRINCETON, NJ, February 3, 2021 – Enalare Therapeutics Inc., a clinical stage biopharmaceutical company dedicated to developing and commercializing novel therapies for patients suffering from life threatening acute respiratory and critical care conditions, announced today that Herm Cukier, President and Chief Executive Officer, and Daniel Motto, Chief Operating Officer, will be presenting at the BIO-Europe Spring Conference scheduled for March 22-25, 2021. The presentation will be recorded and visible for all registered participants to see in advance of the conference. Mr. Cukier and Mr. Motto will also, host one-on-one investor meetings during the three-day event.

About Enalare Therapeutics Inc.

Enalare Therapeutics Inc. is a clinical stage biopharmaceutical company dedicated to developing and commercializing novel therapies for patients suffering from life threatening acute respiratory and critical care conditions, including respiratory depression caused by drug overdose, post-surgery, and pathogens such as COVID-19. The Company is planning to initiate pivotal studies for its lead compound ENA-001 in the near term.

###

CONTACT:

Morgan Wagner
Investor Relations
mwagner@enalare.com